Literature DB >> 24674942

Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study.

Constantine J Karvellas1, Jorge Cavazos2, Holly Battenhouse3, Valerie Durkalski3, Jody Balko2, Corron Sanders2, William M Lee4.   

Abstract

BACKGROUND & AIMS: We investigated whether antimicrobial prophylaxis alters the incidence of bloodstream infection in patients with acute liver failure (ALF), and whether bloodstream infections affect overall mortality within 21 days after development of ALF.
METHODS: We performed a retrospective cohort analysis of 1551 patients with ALF enrolled by the US Acute Liver Failure Study Group from January 1998 through November 2009. We analyzed data on infections in the first 7 days after admission and the effects of prophylaxis with antimicrobial drugs on the development of bloodstream infections and 21-day mortality.
RESULTS: In our study population, 600 patients (39%) received antimicrobial prophylaxis and 226 patients (14.6%) developed at least 1 bloodstream infection. Exposure to antimicrobial drugs did not affect the proportion of patients who developed bloodstream infections (12.8% in patients with prophylaxis vs 15.7% in nonprophylaxed patients; P = .12), but a greater percentage of patients who received prophylaxis received liver transplants (28% vs 22%; P = .01). After adjusting for confounding factors, overall mortality within 21 days was associated independently with age (odds ratio [OR], 1.014), Model for End-stage Liver Disease score at admission (OR, 1.078), and vasopressor administration at admission (OR, 2.499). Low grade of coma (OR, 0.47) and liver transplantation (OR, 0.101) reduced mortality. Although bloodstream infection was associated significantly with 21-day mortality (P = .004), an interaction between bloodstream infection and etiology was detected: blood stream infection affected mortality to a greater extent in nonacetaminophen ALF patients (OR, 2.03) than in acetaminophen ALF patients (OR, 1.14).
CONCLUSIONS: Based on a large, observational study, antimicrobial prophylaxis does not reduce the incidence of bloodstream infection or mortality within 21 days of ALF. However, bloodstream infections were associated with increased 21-day mortality in patients with ALF-to a greater extent in patients without than with acetaminophen-associated ALF. Our findings do not support the routine use of antimicrobial prophylaxis in patients with ALF.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APAP; Antibiotic; Compensatory Anti-inflammatory Response Syndrome; Liver Damage; Systemic Inflammatory Response Syndrome

Mesh:

Year:  2014        PMID: 24674942      PMCID: PMC4205208          DOI: 10.1016/j.cgh.2014.03.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  27 in total

1.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  BMJ       Date:  2007-10-20

Review 2.  The importance of immune dysfunction in determining outcome in acute liver failure.

Authors:  Charalambos Gustav Antoniades; Philip A Berry; Julia A Wendon; Diego Vergani
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

3.  Impaired antigen presentation by human monocytes during endotoxin tolerance.

Authors:  K Wolk; W D Döcke; V von Baehr; H D Volk; R Sabat
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

4.  Blood interleukin 10 levels parallel the severity of septic shock.

Authors:  G Friedman; S Jankowski; A Marchant; M Goldman; R J Kahn; J L Vincent
Journal:  J Crit Care       Date:  1997-12       Impact factor: 3.425

5.  Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure.

Authors:  Lars E Schmidt; Fin Stolze Larsen
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

6.  Timing and aetiology of bacterial infections in a liver intensive care unit.

Authors:  J Wade; N Rolando; J Philpott-Howard; J Wendon
Journal:  J Hosp Infect       Date:  2003-02       Impact factor: 3.926

7.  The systemic inflammatory response syndrome in acute liver failure.

Authors:  N Rolando; J Wade; M Davalos; J Wendon; J Philpott-Howard; R Williams
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

8.  Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock.

Authors:  T Sfeir; D C Saha; M Astiz; E C Rackow
Journal:  Crit Care Med       Date:  2001-01       Impact factor: 7.598

9.  Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma.

Authors:  C Martin; C Boisson; M Haccoun; L Thomachot; J L Mege
Journal:  Crit Care Med       Date:  1997-11       Impact factor: 7.598

10.  Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group.

Authors:  R Todd Stravitz; Andreas H Kramer; Timothy Davern; A Obaid S Shaikh; Stephen H Caldwell; Ravindra L Mehta; Andres T Blei; Robert J Fontana; Brendan M McGuire; Lorenzo Rossaro; Alastair D Smith; William M Lee
Journal:  Crit Care Med       Date:  2007-11       Impact factor: 7.598

View more
  7 in total

1.  Antibiotics in Acute Liver Failure (ALF).

Authors: 
Journal:  J Clin Exp Hepatol       Date:  2015-02-10

Review 2.  Indian National Association for the Study of Liver Consensus Statement on Acute Liver Failure (Part-2): Management of Acute Liver Failure.

Authors:  Anil C Anand; Bhaskar Nandi; Subrat K Acharya; Anil Arora; Sethu Babu; Yogesh Batra; Yogesh K Chawla; Abhijit Chowdhury; Ashok Chaoudhuri; Eapen C Eapen; Harshad Devarbhavi; Radha K Dhiman; Siddhartha Datta Gupta; Ajay Duseja; Dinesh Jothimani; Dharmesh Kapoor; Premashish Kar; Mohamad S Khuroo; Ashish Kumar; Kaushal Madan; Bipadabhanjan Mallick; Rakhi Maiwall; Neelam Mohan; Aabha Nagral; Preetam Nath; Sarat C Panigrahi; Ankush Pawar; Cyriac A Philips; Dibyalochan Prahraj; Pankaj Puri; Amit Rastogi; Vivek A Saraswat; Sanjiv Saigal; Akash Shukla; Shivaram P Singh; Thomas Verghese; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-04-22

Review 3.  Role of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapy.

Authors:  Mhairi C Donnelly; Peter C Hayes; Kenneth J Simpson
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

4.  How to manage: acute liver failure.

Authors:  Oliver D Tavabie; William Bernal
Journal:  Frontline Gastroenterol       Date:  2019-04-29

5.  Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study.

Authors:  Adrian Reuben; Holly Tillman; Robert J Fontana; Timothy Davern; Brendan McGuire; R Todd Stravitz; Valerie Durkalski; Anne M Larson; Iris Liou; Oren Fix; Michael Schilsky; Timothy McCashland; J Eileen Hay; Natalie Murray; Obaid S Shaikh; Daniel Ganger; Atif Zaman; Steven B Han; Raymond T Chung; Alastair Smith; Robert Brown; Jeffrey Crippin; M Edwyn Harrison; David Koch; Santiago Munoz; K Rajender Reddy; Lorenzo Rossaro; Raj Satyanarayana; Tarek Hassanein; A James Hanje; Jody Olson; Ram Subramanian; Constantine Karvellas; Bilal Hameed; Averell H Sherker; Patricia Robuck; William M Lee
Journal:  Ann Intern Med       Date:  2016-04-05       Impact factor: 25.391

6.  Variation in the Care of Acute Liver Failure: A Survey of Intensive Care Professionals.

Authors:  Filipe S Cardoso; Mark J Mcphail; Constantine J Karvellas; Valentin Fuhrmann; Nuno Germano; Georg Auzinger
Journal:  GE Port J Gastroenterol       Date:  2021-05-25

Review 7.  Management of Acute Liver Failure: A Pediatric Perspective.

Authors:  Heli Bhatt; Girish S Rao
Journal:  Curr Pediatr Rep       Date:  2018-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.